Independent directory Public ClinicalTrials.gov records United States
Clinical Trials Finder
Objective public record navigation
Search Results

Search by objective public record fields.

Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.

Clear filters
ClinicalTrials.gov public records Last synced Sep 15, 2026, 7:51 PM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–24 of 39 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Filters: Condition: Post-Surgical Ocular Inflammation Clear all
Completed Phase 4 Interventional

Omidria and Dexycu, or Omidria and Dextenza Compared to Topical Prednisolone Acetate 1% Following Cataract Surgery

NCT04316936
View directory record Official record
Conditions
Cataract Surgery
Interventions
Omidria, Dextenza (dexamethasone ophthalmic insert) 0.4mg, Dexycu, 9% Intraocular Suspension, Prednisolone Acetate 1%
Drug
Lead sponsor
Silverstein Eye Centers
Other
Eligibility
Not listed
Enrollment
15 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
1
States / cities
Kansas City, Missouri
Source: ClinicalTrials.gov public record
Updated Jun 14, 2023 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

Dextenza for Post-operative Treatment of Pterygium

NCT04351737
View directory record Official record
Conditions
Pterygium of Both Eyes
Interventions
Intracanalicular Dexamethasone, (0.4 mg) Insert, Prednisolone Acetate
Drug
Lead sponsor
Brandon Eye Associates, PA
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2020 – 2023
U.S. locations
1
States / cities
Brandon, Florida
Source: ClinicalTrials.gov public record
Updated May 24, 2025 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Efficacy and Safety of APP13007 for Treatment of Inflammation and Pain After Cataract Surgery Including a Corneal Endothelial Cell Sub-study

NCT04810962
View directory record Official record
Conditions
Ocular Inflammation and Pain After Cataract Surgery
Interventions
APP13007, 0.05%, Matching Vehicle Placebo for APP13007, 0.05%
Drug
Lead sponsor
Formosa Pharmaceuticals, Inc.
Industry
Eligibility
18 Years and older
Enrollment
370 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2022
U.S. locations
31
States / cities
Chandler, Arizona • Mesa, Arizona • Phoenix, Arizona + 28 more
Source: ClinicalTrials.gov public record
Updated Jul 24, 2023 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Not applicable Interventional

Will Restasis Eye Drops Increase Your Chance of Having a Successful Surgery?

NCT00405431
View directory record Official record
Conditions
Glaucoma
Interventions
Restasis, Endura (artificial tears)
Drug
Lead sponsor
Wills Eye
Other
Eligibility
18 Years and older
Enrollment
43 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2004 – 2007
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Nov 21, 2016 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

Safety/Efficacy of Nepafenac Punctal Plug Delivery System Compared to Placebo to Control Ocular Pain/Inflammation After Cataract

NCT03496467
View directory record Official record
Conditions
Pain, Inflammation
Interventions
Nepafenac PPDS, Placebo PPDS
Combination Product
Lead sponsor
Mati Therapeutics Inc.
Industry
Eligibility
22 Years to 99 Years
Enrollment
56 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2018
U.S. locations
3
States / cities
Edgewood, Kentucky • Garden City, New York • Mt. Pleasant, South Carolina
Source: ClinicalTrials.gov public record
Updated Oct 11, 2021 · Synced Sep 15, 2026, 7:51 PM EDT
Terminated Phase 1 Interventional Results available

A Safety and Efficacy Study of a Dexamethasone Drug Delivery System for Postoperative Inflammation and Pain After Cataract Surgery

NCT01605942
View directory record Official record
Conditions
Cataract
Interventions
Dexamethasone Drug Delivery System, Placebo Drug Delivery System
Drug
Lead sponsor
Allergan
Industry
Eligibility
18 Years and older
Enrollment
8 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012
U.S. locations
1
States / cities
Newport Beach, California
Source: ClinicalTrials.gov public record
Updated Jun 30, 2015 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 2Phase 3 Interventional Results available

Will the Use of Triesence During Glaucoma Surgery Provide Lower Eye Pressure and Improve the Results of the Surgery?

NCT00853905
View directory record Official record
Conditions
Glaucoma
Interventions
Triesence, balanced salt solution BSS
Drug
Lead sponsor
Wills Eye
Other
Eligibility
21 Years and older
Enrollment
77 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2012
U.S. locations
1
States / cities
Philadelphia, Pennsylvania
Source: ClinicalTrials.gov public record
Updated Jul 9, 2018 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Not applicable Interventional Results available

Prolensa (Bromfenac) 0.07% QD vs. Ilevro (Nepafenac) 0.3% QD for Treatment of Ocular Inflammation Post Cataract Surgery

NCT01847638
View directory record Official record
Conditions
Cataract, Retinal Edema, Inflammation
Interventions
Prolensa (bromfenac 0.07%), Ilevro (nepafenac 0.3%)
Drug
Lead sponsor
Melissa Toyos
Other
Eligibility
18 Years and older
Enrollment
50 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2018
U.S. locations
1
States / cities
Nashville, Tennessee
Source: ClinicalTrials.gov public record
Updated Nov 13, 2018 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

OCS-01 in Treating Inflammation and Pain in Post-cataract Patients

NCT04130802
View directory record Official record
Conditions
Inflammation Corneal, Pain, Postoperative
Interventions
OCS-01 - Dexamethasone Cyclodextrin Nanoparticle Ophthalmic Suspension 1.5% mg/mL, Placebo
Drug
Lead sponsor
Oculis
Industry
Eligibility
18 Years and older
Enrollment
153 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2019 – 2020
U.S. locations
4
States / cities
Petaluma, California • Roseburg, Oregon • Houston, Texas + 1 more
Source: ClinicalTrials.gov public record
Updated Sep 9, 2025 · Synced Sep 15, 2026, 7:51 PM EDT
Terminated Phase 1Phase 2 Interventional

The Effect of Macugen in Patients With Chronic, Post-Operative Cystoid Macular Edema

NCT00358423
View directory record Official record
Conditions
Cystoid Macular Edema
Interventions
Pegaptanib Sodium, Control
Drug
Lead sponsor
Johns Hopkins University
Other
Eligibility
18 Years and older
Enrollment
1 participant
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Baltimore, Maryland
Source: ClinicalTrials.gov public record
Updated May 11, 2008 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

A Comparison of Three Different Formulations of Prednisolone Acetate 1%

NCT00345046
View directory record Official record
Conditions
Glaucoma, Cataract
Interventions
Pred Forte, EconoPred Plus, Prednisolone Acetate
Drug
Lead sponsor
Indiana University
Other
Eligibility
18 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2002 – 2011
U.S. locations
1
States / cities
Indianapolis, Indiana
Source: ClinicalTrials.gov public record
Updated Jun 2, 2015 · Synced Sep 15, 2026, 7:51 PM EDT
Withdrawn Not applicable Interventional Accepts healthy volunteers

Efficacy of Loteprednol Ointment Following Eyelid Surgery

NCT01749241
View directory record Official record
Conditions
Post-operative Healing Following Blepharoplasty and Ptosis Repair
Interventions
Loteprednol etabonate ophthalmic ointment, Vehicle Ophthalmic Ointment
Drug
Lead sponsor
University of California, San Diego
Other
Eligibility
18 Years and older
Healthy volunteers
Accepts healthy volunteers
Timeline
2012 – 2015
U.S. locations
1
States / cities
La Jolla, California
Source: ClinicalTrials.gov public record
Updated Aug 1, 2019 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 1Phase 2 Interventional Results available

A Study of TRS01 in Participants With Post-surgical Ocular Inflammation

NCT04222725
View directory record Official record
Conditions
Post Surgical Ocular Inflammation
Interventions
TRS01 eye drops, Placebo eye drops
Drug
Lead sponsor
Tarsier Pharma
Industry
Eligibility
18 Years and older
Enrollment
37 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020
U.S. locations
5
States / cities
Inglewood, California • Petaluma, California • Washington, Missouri + 2 more
Source: ClinicalTrials.gov public record
Updated Oct 13, 2021 · Synced Sep 15, 2026, 7:51 PM EDT
Not listed Phase 4 Interventional Accepts healthy volunteers

A Study for Post op Inflammation After Cataract Surgery

NCT05665270
View directory record Official record
Conditions
Cataract
Interventions
Dextenza 0.4Mg Ophthalmic Insert, Prednisolone Acetate 1%
Drug
Lead sponsor
Wyse Eyecare
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2023
U.S. locations
1
States / cities
Northbrook, Illinois
Source: ClinicalTrials.gov public record
Updated Apr 25, 2023 · Synced Sep 15, 2026, 7:51 PM EDT
Not listed Phase 4 Interventional

Dextenza Within Upper Lid Canaliculus Compared With Lower Lid Canaliculus Following Bilateral Cataract Extraction Surgery With PCIOL.

NCT04592081
View directory record Official record
Conditions
Post-Surgical Ocular Pain, Post-Surgical Ocular Inflammation
Interventions
Dextenza 0.4Mg Ophthalmic Insert
Drug
Lead sponsor
Kerry Assil, MD
Other
Eligibility
18 Years and older
Enrollment
20 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2020 – 2021
U.S. locations
1
States / cities
Beverly Hills, California
Source: ClinicalTrials.gov public record
Updated Oct 18, 2020 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional

Safety and Efficacy Study of Topical Bromfenac Versus Placebo to Treat Ocular Inflammation After Cataract Surgery

NCT00198445
View directory record Official record
Conditions
Postoperative Complications, Cataract
Interventions
Bromfenac, Placebo
Drug
Lead sponsor
Bausch & Lomb Incorporated
Industry
Eligibility
18 Years and older
Enrollment
527 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2003 – 2004
U.S. locations
39
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Irvine, California + 34 more
Source: ClinicalTrials.gov public record
Updated Mar 13, 2013 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Results available

Study of Efficacy and Safety of Vigadexa in Treating Inflammation and Infection Post-cataract Surgery

NCT00870103
View directory record Official record
Conditions
Cataract
Interventions
Vigadexa (moxifloxacin 0.5% and dexamethasone 0.1%) eye drops
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
18 Years and older
Enrollment
64 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2008
U.S. locations
1
States / cities
Fort Worth, Texas
Source: ClinicalTrials.gov public record
Updated Mar 8, 2010 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 2 Interventional Results available

Phase II Study Evaluating Safety/Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT01666210
View directory record Official record
Conditions
Ocular Inflammation and Pain
Interventions
OTX-DP (Dexamethasone punctum plug), Placebo Vehicle Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
21 Years and older
Enrollment
60 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2012 – 2013
U.S. locations
1
States / cities
Hoffman Estates, Illinois
Source: ClinicalTrials.gov public record
Updated Oct 18, 2021 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation and Pain

NCT02508337
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
309 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2015 – 2016
U.S. locations
1
States / cities
Andover, Massachusetts
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional

Efficacy and Safety of XG-102 in Reduction of Post-cataract Surgery Intraocular Inflammation

NCT02235272
View directory record Official record
Conditions
Inflammation, Pain, Cataract
Interventions
XG-102, Placebo
Drug
Lead sponsor
Xigen SA
Industry
Eligibility
18 Years and older
Enrollment
339 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Garden Grove, California
Source: ClinicalTrials.gov public record
Updated Jan 23, 2017 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 4 Interventional

Comparison of Acular LS With Lotemax to Prevent Inflammation After Cataract Surgery and Intraocular Lens Implantation

NCT00366691
View directory record Official record
Conditions
Cataract Extraction
Interventions
Acular LS, Lotemax
Drug
Lead sponsor
Medical University of South Carolina
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2006 – 2007
U.S. locations
1
States / cities
Charleston, South Carolina
Source: ClinicalTrials.gov public record
Updated Jun 13, 2018 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional Results available

Phase 3 Study Evaluating Safety and Efficacy of OTX-DP for Treatment of Ocular Inflammation and Pain After Cataract Surgery

NCT02034019
View directory record Official record
Conditions
Post Ocular Surgical Inflammation and Pain
Interventions
Dexamethasone, Punctum Plug
Drug
Lead sponsor
Ocular Therapeutix, Inc.
Industry
Eligibility
18 Years and older
Enrollment
247 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2014 – 2015
U.S. locations
1
States / cities
Austin, Texas
Source: ClinicalTrials.gov public record
Updated Jan 30, 2020 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 4 Interventional Accepts healthy volunteers

A Prospective Clinical Study Evaluating Dexycu vs Prednisolone Acetate 1%

NCT04273282
View directory record Official record
Conditions
Cataract
Interventions
Dexycu intracameral dexamethasone, Prednisolone Acetate
Drug
Lead sponsor
Research Insight LLC
Industry
Eligibility
18 Years and older
Enrollment
31 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2019 – 2020
U.S. locations
2
States / cities
Laguna Hills, California • Garden City, New York
Source: ClinicalTrials.gov public record
Updated Dec 10, 2020 · Synced Sep 15, 2026, 7:51 PM EDT
Completed Phase 3 Interventional

Nepafenac Opthalmic Suspension 0.1% Compared to Acular LS for Treatment of Inflammation After Cataract Surgery

NCT00333255
View directory record Official record
Conditions
Cataract
Interventions
Nepafenac Ophthalmic Suspension, 0.1%
Drug
Lead sponsor
Alcon Research
Industry
Eligibility
10 Years and older
Enrollment
267 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
Started 2005
U.S. locations
1
States / cities
Nacogdoches, Texas
Source: ClinicalTrials.gov public record
Updated Jul 7, 2009 · Synced Sep 15, 2026, 7:51 PM EDT